Brought to you by 
Series A for neuroscience company NuPathe grosses $15mm
21 Sep 2006
Executive Summary
NuPathe (drug delivery technologies for neurological and psychiatric diseases) has raised $15mm in a Series A financing that was co-led by Birchmere Ventures and BioAdvance Ventures. Safeguard Scientifics also participated and will contribute a new member to NuPathe's board.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
-
Drug Delivery
- Controlled Release
- Transdermal
-
Medical Devices
- Biomaterials
- Implantable Devices
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Series A for neuroscience company NuPathe grosses $15mm
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice